These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26358138)

  • 1. Antifibrotic mechanism of deferoxamine in concanavalin A induced-liver fibrosis: Impact on interferon therapy.
    Darwish SF; El-Bakly WM; El-Naga RN; Awad AS; El-Demerdash E
    Biochem Pharmacol; 2015 Nov; 98(1):231-42. PubMed ID: 26358138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferoxamine alleviates liver fibrosis induced by CCl4 in rats.
    Mohammed A; Abd Al Haleem EN; El-Bakly WM; El-Demerdash E
    Clin Exp Pharmacol Physiol; 2016 Aug; 43(8):760-8. PubMed ID: 27168353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential antifibrotic impact of apocynin and alpha-lipoic acid in concanavalin A-induced liver fibrosis in rats: Role of NADPH oxidases 1 and 4.
    Fayed MR; El-Naga RN; Akool ES; El-Demerdash E
    Drug Discov Ther; 2018; 12(2):58-67. PubMed ID: 29760339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depletion of serotonin relieves concanavalin A-induced liver fibrosis in mice by inhibiting inflammation, oxidative stress, and TGF-β1/Smads signaling pathway.
    Pang Q; Jin H; Wang Y; Dai M; Liu S; Tan Y; Liu H; Lu Z
    Toxicol Lett; 2021 Apr; 340():123-132. PubMed ID: 33429011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic aspects of antifibrotic effects of honokiol in Con A-induced liver fibrosis in rats: Emphasis on TGF-β/SMAD/MAPK signaling pathways.
    Elfeky MG; Mantawy EM; Gad AM; Fawzy HM; El-Demerdash E
    Life Sci; 2020 Jan; 240():117096. PubMed ID: 31760097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron chelation by deferasirox confers protection against concanavalin A-induced liver fibrosis: A mechanistic approach.
    Adel N; Mantawy EM; El-Sherbiny DA; El-Demerdash E
    Toxicol Appl Pharmacol; 2019 Nov; 382():114748. PubMed ID: 31499193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.
    Sikorska K; Stalke P; Izycka-Swieszewska E; Romanowski T; Bielawski KP
    Med Sci Monit; 2010 Mar; 16(3):CR137-143. PubMed ID: 20190684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C.
    Nanba S; Ikeda F; Baba N; Takaguchi K; Senoh T; Nagano T; Seki H; Takeuchi Y; Moritou Y; Yasunaka T; Ohnishi H; Miyake Y; Takaki A; Nouso K; Iwasaki Y; Yamamoto K
    J Clin Pathol; 2016 Mar; 69(3):226-33. PubMed ID: 26290259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of antifibrotic drug halofugine on Th17 cells in concanavalin A-induced liver fibrosis.
    Liang J; Zhang B; Shen RW; Liu JB; Gao MH; Geng X; Li Y; Li YY; Zhang W
    Scand J Immunol; 2014 Mar; 79(3):163-72. PubMed ID: 24383550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased oxidative stress in dimethylnitrosamine-induced liver fibrosis in the rat: effect of N-acetylcysteine and interferon-alpha.
    Vendemiale G; Grattagliano I; Caruso ML; Serviddio G; Valentini AM; Pirrelli M; Altomare E
    Toxicol Appl Pharmacol; 2001 Sep; 175(2):130-9. PubMed ID: 11543645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of pegylated interferon alpha 2b on bile-duct ligation induced liver fibrosis in rats.
    Canbakan B; Akin H; Tahan G; Tarcin O; Eren F; Atug O; Tahan V; Imeryuz N; Yapicier O; Avsar E; Tozun N
    Ann Hepatol; 2009; 8(3):234-40. PubMed ID: 19841503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
    Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
    Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rat liver fibrosis regresses better with pegylated interferon alpha2b and ursodeoxycholic acid treatments than spontaneous recovery.
    Tasci I; Mas MR; Vural SA; Comert B; Alcigir G; Serdar M; Mas N; Isik AT; Ates Y
    Liver Int; 2006 Mar; 26(2):261-8. PubMed ID: 16448466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
    Lange CM; Kutalik Z; Morikawa K; Bibert S; Cerny A; Dollenmaier G; Dufour JF; Gerlach TJ; Heim MH; Malinverni R; Müllhaupt B; Negro F; Moradpour D; Bochud PY;
    Hepatology; 2012 Apr; 55(4):1038-47. PubMed ID: 22095909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.
    Roffi L; Colloredo G; Pioltelli P; Bellati G; Pozzpi M; Parravicini P; Bellia V; Del Poggio P; Fornaciari G; Ceriani R; Ramella G; Corradi C; Rossini A; Bruno S;
    Antivir Ther; 2008; 13(5):663-73. PubMed ID: 18771050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis.
    Maan R; van der Meer AJ; Hansen BE; Feld JJ; Wedemeyer H; Dufour JF; Zangneh HF; Lammert F; Manns MP; Zeuzem S; Janssen HL; de Knegt RJ; Veldt BJ
    J Hepatol; 2014 Sep; 61(3):482-91. PubMed ID: 24780302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis.
    Tanwar S; Wright M; Foster GR; Ryder SD; Mills PR; Cramp ME; Parkes J; Rosenberg WM
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):543-50. PubMed ID: 22337287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
    Mukherjee S; Lyden E
    Hepatogastroenterology; 2006; 53(70):561-5. PubMed ID: 16995462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.